4D Molecular Therapeutics

At 4DMT, we believe in innovation with a purpose. Our Co-founder & CEO, David Kirn, MD, recently joined Cell & Gene’s Tyler Menichiello to discuss how we are leveraging the principles of directed evolution to develop novel, customized vectors designed to treat a wide range of diseases such as #WetAMD and #DiabeticMacularEdema (DME) with unprecedented precision. Learn more about our science, pipeline and recent clinical progress by reading the full article: https://lnkd.in/eUWeTZjp #GeneticMedicines

Featured in The Ophthalmologist 2024 Retina Round-Up, Arshad M. Khanani highlights the promising results of 4D-150 from the PRISM Phase 1/2 study, presented at EURETINA in September, and its potential to address the ongoing challenges faced by patients living with wet AMD. We were honored to have him present our data and its inclusion in The Ophthalmologist’s Retina newsletter. We are looking forward to sharing our 52-week results in February. Stay tuned! #RetinalDisease #Ophthalmology 

4D-150 preclinical data was published in the December 2024 issue of Investigative Ophthalmology & Visual Science (IOVS), a journal of the Association for Research in Vision and Ophthalmology (ARVO). The data demonstrate the potential of our proprietary R100 vector and the R100-based genetic medicine 4D-150 to substantially reduce the treatment burden and improve long-term vision outcomes for patients with wet age-related macular degeneration (#wetAMD), #DiabeticMacularEdema (DME) and diabetic retinopathy (DR). In addition, a 3D rendering of the R100 vector was featured on the cover of the journal.     Learn more: https://lnkd.in/eK3HwnXS    #RetinalDisease #Ophthalmology 

At 4DMT, we’re inspired by our guiding principles to focus awareness on social equity and create positive change not only within 4DMT, but in our community at large. Last month, our team worked with the Alameda County Community Food Bank for an unforgettable volunteer day. We learned about their incredible operations distributing food across 14 cities, actively participated in tasks such as onion sorting and crate building, and even appeared in the Food Bank’s video showcasing their freshly harvested kale! Thank you to our volunteers for making a difference in our community!   #CommunityImpact #VolunteerDay #BeyondYourself

Our Chief Financial & Business Officer, Uneek Mehra, and Chief Development Officer, Dhaval B. Desai, PharmD, joined a #firesidechat with Jonathan Miller at the Evercore ISI HealthCONx Conference this week to discuss our clinical programs, innovative approach and commitment to unlocking the full potential of #geneticmedicines for large market diseases.   Thank you to everyone who attended, we appreciate the opportunity to share our vision and mission to provide transformative benefits for patients. Missed the event? Access the full webcast here: https://bit.ly/3VnUjP0 #HealthCONx2024 #Biotech

Our Chief Financial & Business Officer, Uneek Mehra, and Chief Development Officer, Dhaval B. Desai, PharmD, shared insights on 4DMT’s clinical programs and explored the advancements shaping the future of #GeneticMedicines at the Jefferies London Healthcare Conference last week.   Our team enjoyed connecting with leaders and innovators across the global biotech and investment communities. Thank you to everyone who joined us for meaningful conversations.   #JefferiesHealthcare

Our management team will be at the Evercore ISI HealthCONx Conference in Coral Gables, FL, next week for 1x1 meetings and to present at a fireside chat. Register for our webcast here: https://lnkd.in/eMRz7gXa #HealthCONx2024 #Healthcare

We are thrilled to share that we have expanded our office at 5858 Horton, enabling us to foster greater collaboration, enhance our research capabilities and support our growing team as we ready for the launch of our global Phase 3 4FRONT program for 4D-150 in #wetAMD. This growth reflects our commitment to bold innovation and relentless execution as we continue to break boundaries and revolutionize #geneticmedicine for millions of patients in need.

Alpha-1 Antitrypsin Deficiency (Alpha-1 or A1AT) is a condition that affects around 200,000 individuals in the United States and Europe, yet significant unmet medical need remains despite existing therapies. Join us this #Alpha1AwarenessMonth to support this year’s theme, “The Power to Connect,” highlighting the importance of connecting with the Alpha-1 community, and advocating for those in need of a cure. Learn more here: https://lnkd.in/gKMhjiKp #Alpha1 #LungDisease

This week, Carlos Quezada Ruiz, M.D., FASRS, our SVP, Therapeutic Area Head, Ophthalmology, will be presenting at the Ophthalmology Innovation Summit in San Diego, CA. Join him to learn more about our potentially transformative #geneticmedicine approach to large market #ophthalmic diseases. Learn more: https://lnkd.in/eMRz7gXa Ophthalmology Innovation Source | #OISXIV #ophthalmology